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Abstract
Patients with extensive, long-standing colonic inﬂammatory bowel disease have a greater risk of developing colorectal
cancer (CRC) than the general population. The prevalence of CRC in patients with ulcerative colitis (UC) is approximately
3.7% on average, being 2% at 10 years and 19% at 30 years from diagnosis. Furthermore, CRC is the third leading cause of
death in patients with UC. Based on these data, periodic follow-up colonoscopies in all patients with long-standing UC and
colonic Crohn’s disease are recommended. However, detection of colitis-associated dysplasia and cancer during follow-up
endoscopy is complex, as these lesions are multifocal and often sit on normal-appearing mucosa. Surveillance guidelines
recommend that in addition to targeted biopsies from suspicious lesions, 2–4 random biopsies should be taken every
10 cm of colon. Despite this laborious routine, colitis-associated lesions are often missed by routine white-light endoscopy
with random biopsies. In recent years, several studies have demonstrated that chromoendoscopy (CE) is more
proﬁtable than conventional endoscopy for the detection of foci of dysplasia in patients with long-standing UC. In fact,
recent consensus guidelines have endorsed the use of CE as standard in this subset of patients. Furthermore, recent
evidence demonstrates that CE-directed biopsies have a higher diagnostic yield than random biopsies. From these studies it
appears that CE-targeted biopsy is the most proﬁtable strategy, and the role of random biopsy sampling is seriously
questioned. However, both approaches have drawbacks: few endoscopists perform the required 30–40 biopsies in
routine practice because this method is time consuming and expensive, and gastroenterologists have been reluctant to take
up CE, possibly due to concerns regarding procedure time and lack of experience. Nevertheless, CE is an inexpensive
and technically attainable method that only needs intention and dedication from the endoscopist. This video shows
how to perform CE and how to interpret the different lesions detected during CE surveillance in a patient with
long-standing UC. This article is part of an expert video encyclopedia.
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Video Related to this Article
Materials
• Video colonoscope: Olympus H180 (Olympus Europe).
• Video processor: Olympus Exera II (Olympus Europe).
• Spray catheter: Olympus PW-5V1 (Olympus Europe).
• Indigo carmine 0.5% (pharmaceutical formula).
Background and Endoscopic Procedures
Background
Patients with extensive, long-standing colonic inﬂammatory
bowel disease have a greater risk of developing colorectal
cancer (CRC) than the general population. The prevalence of
CRC in patients with ulcerative colitis (UC) is approximately
3.7% on average, 2% at 10 years, and 19% at 30 years from
diagnosis. Furthermore, CRC is the third leading cause of
death in patients with UC. Based on these data, periodic fol-
low-up colonoscopies in all patients with long-standing UC
and colonic Crohn’s disease are recommended. However,
detection of colitis-associated dysplasia and cancer during
follow-up endoscopy is complex, as these lesions are
multifocal and often sit on normal-appearing mucosa. Sur-
veillance guidelines recommend that in addition to targeted
biopsies from suspicious lesions, 2–4 random biopsies should
be taken every 10 cm of colon. Despite this laborious routine,
colitis-associated lesions are often missed by routine white-
light endoscopy with random biopsies. In recent years, several
studies have demonstrated that chromoendoscopy (CE) is
more proﬁtable than conventional endoscopy for the de-
tection of foci of dysplasia in patients with long-standing UC.
In fact, recent consensus guidelines have endorsed the use
of CE as standard in this subset of patients. Furthermore,
recent evidence demonstrates that CE-directed biopsies have a
higher diagnostic yield than random biopsies. From these
studies it appears that CE-targeted biopsy is the most
proﬁtable strategy, and the role of random biopsy sampling is
seriously questioned. However, both approaches have draw-
backs: few endoscopists perform the required 30–40 biopsies
in routine practice because this method is time consuming
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and expensive, and gastroenterologists have been reluctant to
take up CE, possibly due to concerns regarding procedure
time, and lack of experience. Nevertheless, CE is an inexpen-
sive and technically attainable method that only needs in-
tention and dedication from the endoscopist.
The video for this article shows how to perform chro-
moendoscopy and how to interpret the different lesions de-
tected during chromoendoscopy surveillance in a patient with
long-standing UC.
Endoscopic Procedures
• Reach the cecum.
• Cleaning by segments with a water pump. N-acetylcysteine
in the water to facilitate mucous retrieval.
• Spraying indigo carmine with a spray catheter by segments.
• Careful inspection of the mucosa in each segment.
• Biopsy suspicious lesion: well-demarcated lesions, dis-
ruption of innominate lines, changing in mucosal pit
pattern, altered vascularization.
• Biopsy mucosa around suspicious malignant lesions.
• Biopsy normal mucosa in each segment to assess histo-
logical activity.
• Random biopsies in stenotic segments and disorganized
areas with pseudopolyps.
Key Learning Points/Tips and Tricks
• Adequate patient selection.
• Patient in clinical remission.
• Adequate bowel cleansing.
• Use the best endoscope.
• Adequate time scheduled: 60 min.
• Dedicate endoscopist.
• Be systematic: reach the cecum; cleaning; spraying indigo
carmine and inspecting by segments; careful inspection of
the mucosa in each segment.
• Biopsy suspicious lesion: well-demarcated lesions, dis-
ruption of innominate lines, changing in mucosal pit
pattern, altered vascularization.
• Biopsy mucosa around suspicious malignant lesions.
• Biopsy normal mucosa in each segment to assess histo-
logical activity.
• Random biopsies in stenotic segments and disorganized
areas with pseudopolyps.
Scripted Voiceover
00:00 Here we present a 36-year-old male with a 13 year
longstanding ulcerative pancolitis. He has no personal
or familial history of colorectal cancer. A
chromoendoscopy is performed for colorectal cancer
screening. To perform a screening colonoscopy the
patient has to be in clinical remission. Moreover, an
accurate bowel cleansing is mandatory. After reaching
the cecum, initial assessment of each segment of the
colonic mucosa is performed under white light
endoscopy, while residual feces are cleaned with a
water pump. Next, a non-absorptive dyestuff (indigo
carmine) is applied by segments using a spray catheter.
Chromoendoscopy allows a highly detailed assessment
of the colonic mucosae. An exhaustive inspection of
each segment is warranted: well demarcated lesions,
disruption of innominate lines, changing in mucosal pit
pattern, and altered vascularization.
01:10 Notice a slightly raised lesion, easily identiﬁed with
chromoendoscopy. Borders are well demarcated,
innominate lines disrupted and, a mucosal pit pattern
Kudo type II and IIIL is identiﬁed. The lesion has a
depressed area with loss of mucosal pit pattern
suggesting dysplastic changes. The lesion is biopsied at
the edge to conﬁrm the malignant histology. It is also
important to perform biopsies in the surrounding tissue
to assess the future therapeutic attitude. In this case,
this lesion harbored low grade dysplasia. Biopsies from
the surrounding tissue showed quiescent colitis without
dysplasia.
02:10 In this sequence, the ‘‘tubular colon’’ observed is
secondary to the absence of haustra. This is believed to
be the consequence of the chronic inﬂammatory
process and is a predictive factor for dysplasia.
02:35 Observe this 2 mm ﬂat-elevated lesion, round shaped,
well circumscribed. Once again, innominate lines are
disrupted. Mucosal pit pattern is similar to normal
surrounding tissue (Kudo type I). These features
suggest a diagnosis of hyperplastic polyp. The lesion is
removed with biopsy forceps to assure a histopathology
specimen.
03:23 In the following, we describe an irregular patch covered
by a velvety surface and faded limits. Lateral extension
can be seen in this image. This lesion contains
protruded areas with mucosal pit pattern Kudo type II,
as well as innominate lines crossing the lesion. The fact
that innominate lines are not disrupted and pit pattern is
not altered could indicate a benign lesion. However, in
this setting directed biopsies should be obtained from
any suspicious lesion, since Kudo pit pattern is not as
accurate as for sporadic cancer. In this case,
histopathology was diagnostic of low grade dysplasia
and biopsies from surrounding mucosa were normal.
04:36 We observe a 5 mm sessile polyp (Paris classiﬁcation Is).
The lesion is well circumscribed and looks like a
sporadic adenoma. A Kudo mucosal pit pattern type IV
is easily identiﬁed suggesting a low grade dysplastic
adenoma. Sporadic-like lesions can also be naturally
described in patients with long-standing inﬂammatory
bowel disease. Management of this type of lesion does
not differ from those in the general population. The
polyp is removed with a snare polypectomy. In this
setting, it is important to remember that biopsies from
surrounding mucosa should be obtained even if the
lesion looks like a sporadic adenoma.
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